- Home
- CRDF vs AQST Comparison
CRDF vs AQST Comparison
Compare CRDF & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRDF | AQST |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.1M | 809.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CRDF | AQST |
|---|---|---|
| Price | $2.56 | $5.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $10.63 | $8.83 |
| AVG Volume (30 Days) | 914.5K | ★ 2.3M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $501,000.00 | ★ $43,397,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $52.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.90 | $2.12 |
| 52 Week High | $5.00 | $7.55 |
Technical Indicators
Market Signals| Indicator | CRDF | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 65.93 | 44.66 |
| Support Level | $2.32 | $5.61 |
| Resistance Level | $2.59 | $6.44 |
| Average True Range (ATR) | 0.13 | 0.31 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 94.69 | 16.00 |
Price Performance
Historical ComparisonAbout CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.